Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Ritonavir (Norvir) Research

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common (February 6, 2008)
From The Body PRO
Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers (February 4, 2008)
Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.
From The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.